09.05.2024 22:19:12 - dpa-AFX: Nektar Therapeutics Q1 Loss Drops In Line With Estimates

WASHINGTON (dpa-AFX) - Nektar Therapeutics (NKTR) revealed Loss for first
quarter that decreased from last year in line with the Street estimates.

The company's bottom line totaled -$36.80 million, or -$0.19 per share. This
compares with -$137.02 million, or -$0.73 per share, in last year's first
quarter.

Analysts on average had expected the company to earn -$0.19 per share, according
to figures compiled by Thomson Reuters. Analysts' estimates typically exclude
special items.

The company's revenue for the quarter rose 0.2% to $21.64 million from $21.59
million last year.

Nektar Therapeutics earnings at a glance (GAAP) :

-Earnings (Q1): -$36.80 Mln. vs. -$137.02 Mln. last year.
-EPS (Q1): -$0.19 vs. -$0.73 last year.
-Revenue (Q1): $21.64 Mln vs. $21.59 Mln last year.


Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX
Name WKN Börse Kurs Datum/Zeit Diff. Diff. % Geld Brief Erster Schluss
NEKTAR THERAPEUTICS 165417 Frankfurt 1,590 23.05.24 08:08:56 +0,051 +3,31% 1,563 1,618 1,590 1,539

© 2000-2024 DZ BANK AG. Bitte beachten Sie die Nutzungsbedingungen | Impressum
2024 Infront Financial Technology GmbH